Annovis Bio (ANVS) is trading up at $1.20 (+1.69%), as of the latest quote. It operates in the Health Care sector.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$1.61M | −$6.64M | −$14.5M | −$25.5M | −$45.0M | −$26.7M | −$29.7M |
| Net income | −$991.0K | −$5.46M | −$14.5M | −$25.3M | −$56.2M | −$24.6M | −$28.9M |
| EPS (diluted) | −$3.51 | −$0.87 | −$1.90 | −$3.10 | −$6.23 | −$2.31 | −$1.40 |
| Balance sheet | |||||||
| Cash and equivalents | $1.86K | $8.07M | $45.7M | $28.4M | $5.75M | $10.6M | $19.5M |
| Total assets | $1.12M | $8.12M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M |
| Total liabilities | $2.62M | $578.4K | $1.51M | $7.70M | $18.0M | $4.62M | $4.23M |
| Shareholders' equity | −$8.58M | $7.54M | $44.5M | $28.3M | −$7.75M | $9.31M | $16.9M |
| Cash flow | |||||||
| Operating cash flow | −$476.5K | −$3.97M | −$9.13M | −$17.3M | −$40.0M | −$21.9M | −$25.6M |
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
| Operating income | −$4.39M | — | −$6.28M | −$6.27M | −$7.43M | — | −$18.0M | −$14.4M |
| Net income | −$12.6M | — | −$5.54M | −$6.22M | −$7.26M | — | −$17.6M | −$14.8M |
| EPS (diluted) | −$0.97 | — | −$0.32 | −$0.32 | −$0.37 | — | −$0.63 | −$0.40 |
| Balance sheet | ||||||||
| Cash and equivalents | $12.6M | $10.6M | $22.2M | $17.1M | $15.3M | $19.5M | $14.2M | $18.7M |
| Total assets | $14.4M | $13.9M | $26.7M | $21.5M | $17.2M | $21.1M | $16.2M | $22.0M |
| Total liabilities | $7.30M | $4.62M | $2.68M | $3.12M | $4.03M | $4.23M | $13.1M | $26.3M |
| Shareholders' equity | $7.06M | $9.31M | $24.1M | $18.3M | $13.2M | $16.9M | $3.13M | −$4.25M |
| Cash flow | ||||||||
| Operating cash flow | −$3.20M | — | −$8.10M | −$5.11M | −$3.49M | — | −$9.01M | −$21.9M |
From Annovis Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Annovis Bio in our feed yet.